Some reports suggested that CML patients with KIR2DL5B and KIR2DL2 alleles reached higher DMR after TKIs, implying that some KIR alleles or a specific combination of KIR genes can modify NK cell activity against CML cells [77,78]. Here, KIR3DL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.